PROTEA - Sectoral Biotech Opportunities Fund IF H CHF hedged

Reference Data

ISIN LU1711916616
Valor Number 38954344
Bloomberg Global ID
Fund Name PROTEA - Sectoral Biotech Opportunities Fund IF H CHF hedged
Fund Provider Sectoral Asset Management Inc 1010 Sherbrooke St. West, Suite 1610
QC H3A 2R7 Montreal
Canada
Phone: +1 514 849 8777
E-Mail: BusinessDevelopment@sectoral.com
Fund Provider Sectoral Asset Management Inc
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** This Sub-Fund aims to achieve capital growth in USD. While respecting the principle of risk diversification, the Sub-Fund’s assets are primarily invested in equities, equity-like transferable securities, participation certificates etc. issued by particularly innovative small, mid and large cap biotech companies worldwide which are active in the human medicine sector and depositary receipts, such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs), referring to such securities. While no geographical restrictions apply re. specific countries or regions, the industry and therefore the Sub-Fund’s investments are centered in North America and Western Europe.
Peculiarities

Fund Prices

Current Price * 8.85 CHF 31.10.2024
Previous Price * 8.96 CHF 30.10.2024
52 Week High * 9.43 CHF 21.08.2024
52 Week Low * 7.70 CHF 09.11.2023
NAV * 8.85 CHF 31.10.2024
Issue Price * 8.85 CHF 31.10.2024
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 22,857,438
Unit/Share Assets *** 1,547,552
Trading Information SIX

Performance

YTD Performance -1.99% 29.12.2023
31.10.2024
1 month -2.75% 30.09.2024
31.10.2024
3 months -4.74% 31.07.2024
31.10.2024
6 months +7.80% 30.04.2024
31.10.2024
1 year +14.49% 31.10.2023
31.10.2024
2 years +2.67% 31.10.2022
31.10.2024
3 years -23.04% 02.11.2021
31.10.2024
5 years +19.43% 31.10.2019
31.10.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Gilead Sciences Inc 9.90%
Regeneron Pharmaceuticals Inc 8.57%
Amgen Inc 6.33%
Vertex Pharmaceuticals Inc 6.24%
AstraZeneca PLC ADR 4.63%
Alnylam Pharmaceuticals Inc 4.07%
Biogen Inc 3.26%
argenx SE ADR 2.90%
Moderna Inc 2.60%
Biomarin Pharmaceutical Inc 2.43%
Last data update 30.09.2024

Cost / Risk

TER 1.45%
TER date 30.06.2023
Performance Fee ***
PTR
Max. Management Fee *** 1.10%
Ongoing Charges *** 1.31%
SRRI ***
SRRI date *** 30.09.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)